New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.

ABSTRACT: The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as well as adjuvant targeted therapy. As of January 2024, marketing authorization has been granted for four new indications in Europe, and regulatory approvals for other study regimens are expected. Because cost-effectiveness and reimbursement criteria for novel treatments often differ between European countries, access to emerging developments may lead to inequalities due to variations in recommended and available lung cancer care throughout Europe. This Series paper (i) highlights the clinical studies reshaping the treatment landscape in resectable early-stage NSCLC, (ii) co

SUBMITTER: Houda I 

PROVIDER: S-EPMC10928304 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature